Apomorphine subcutaneous - Britannia Pharmaceuticals
Alternative Names: APO-go; Apokinon; Apokyn; Apomine; Britaject; KW-6500; Li Ke Ji; MOVAPO®; SPN-830Latest Information Update: 15 May 2024
At a glance
- Originator Britannia Pharmaceuticals
- Developer Britannia Pharmaceuticals; Kyowa Kirin; STADA Arzneimittel; Supernus Pharmaceuticals; US WorldMeds
- Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Quinolines; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Parkinson's disease
Most Recent Events
- 08 May 2024 Supernus Pharmaceuticals intends to resubmit the NDA following further discussions with the FDA, which is expected in May 2024
- 08 Apr 2024 Supernus Pharmaceuticals receives complete response letter from the US FDA for SPN 830 in Parkinson's disease
- 02 Nov 2023 FDA assigns PDUFA action date of 5/04/2024 for apomorphine subcutaneous for Parkinson’s disease (Infusion pump)